



Attorney Docket No. 2543-1-034

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Jonathan A. Terrett

SERIAL NO.: 10/736,461

EXAMINER: Unassigned

DATE FILED: December 15, 2003

ART UNIT: 1645

FOR: CANCER ASSOCIATED PROTEIN

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2004.

Karen Garipoli
(Name of Depositor)

Karen Garipoli 6/30/04
(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BA** through **CO** listed on the attached Form

PTO-1449. However, with respect to Reference **BC**, please note that due to the size of the reference (2,104 pages), a CD containing reference WO 00/55351 in Adobe .pdf format is enclosed in place of a printed copy. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,



David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
201-487-5800



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-034
	SERIAL NO.	10/736,461
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	JP11146790 ABSTRACT	6/2/99	JAPAN			
	BB	WO 01/98318	12/27/01	PCT			
	BC	WO 00/55351	9/21/00	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™)Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts ¹ , 1998, Cancer Res. 58: 2825-2831
CB	Catimel, B., et al.,Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium, 1996, J. Biol. Chem. 271:25664-25670
CC	Davis, ID,et al,An overview of Cancer immunotherapy 2000, Immunol. Cell Biol. 78: 179-196
CD	Dillman, R.O.,Perceptions of Herceptin®:A Monoclonal Antibody for the Treatment of Breast Cancer,1999, Cancer Biother. Radiopham. 14: 5-10
CE	Green,MC,etal,Monoclonal antibody therapy for solid tumors,2000,Cancer Treat Rev 26:269-86
CF	Hastbacka J,et al,The Diastrophic Dysplasia Gene Encodes a Novel Sulfate Transporter Positional Cloning by Fine-Structure Linkage Disequilibrium Mapping,1994,Cell 78(6):1073-87
CG	Hastbacka J., et al.,Atelosteogenesis Type II Is Caused by Mutations in the Diastrophic Displasia Sulfate-Transporter Gene(DTDST):Evidence for a Phenotypic Series Involving Three Chondrodysplasias, 1996, Am. J. Hum. Genet.58(2):255-62
EXAMINER: _____ DATE CONSIDERED: _____	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY. DOCKET NO.	2543-1-034
	SERIAL NO.	10/736,461
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CH	Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528
	CI	Knuth, A. et al., Cancer immunotherapy in clinical oncology 2000, Cancer Chemother. Pharmacol. 46, S46-51
	CJ	Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression 2000, Int.J. Cancer 87:55-60
	CK	Miller, K.D., et al., Toward checkmate:biology and breast cancer therapy for the new millennium 1999, Invest.New Drugs 17: 417-427
	CL	Saffran, D.C., et al., Target antigens for prostate cancer immunotherapy 1999, Cancer Metastasis Rev. 18: 437-449
	CM	Shiku, H., et al., Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82
	CN	Stebbing, J., et al., Herceptin (trastuzumab) in advanced breast cancer 2000, Cancer Treat. Rev. 26:287-290
	CO	Superti-Furga A., et al., Achondrogenesis type IB is caused by mutations i the diastrophic dysplasia sulphate transporter gene,1996, Nature Genet. 12(1):100-2
EXAMINER:		DATE CONSIDERED:
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>		